AstraZeneca (AZN) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for AstraZeneca (NYSE: AZN):

  • 2/6/2018 – AstraZeneca had its price target raised by analysts at Leerink Swann from $36.00 to $38.00. They now have a “market perform” rating on the stock.
  • 2/5/2018 – AstraZeneca had its price target raised by analysts at Sanford C. Bernstein from $40.00 to $42.00. They now have an “outperform” rating on the stock.
  • 2/4/2018 – AstraZeneca had its “buy” rating reaffirmed by analysts at BMO Capital Markets.
  • 2/3/2018 – AstraZeneca was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 1/26/2018 – AstraZeneca had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $38.00 price target on the stock.
  • 1/22/2018 – AstraZeneca was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AstraZeneca’s core products like Nexium, Seroquel and Crestor are facing generic competition, which is hurting sales. The diabetes franchise also faces stiff competition. Nonetheless, AstraZeneca’s newer drugs like Tagrisso and Brilinta should keep contributing to the top line. Meanwhile, cost-cutting initiatives should drive the bottom line. AstraZeneca also has a promising late-stage pipeline that includes immuno-oncology candidates.  Imfinzi, approved for bladder cancer and currently being evaluated for multiple cancers, is a key drug in the pipeline. AstraZeneca announced quite a few positive developments on the regulatory and pipeline front in 2017, which has led shares to outperform the industry in the past one year. Estimate movement has been mixed ahead of Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters.”
  • 1/18/2018 – AstraZeneca had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $36.00 price target on the stock, up previously from $33.00.
  • 1/10/2018 – AstraZeneca was given a new $38.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 1/10/2018 – AstraZeneca was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AstraZeneca is one of the key players in the global cardiovascular market. However, AstraZeneca’s core products like Nexium, Seroquel and Crestor are facing generic competition, which is hurting sales. The diabetes franchise also faces stiff competition. Nonetheless, AstraZeneca’s newer drugs like Tagrisso and Brilinta should keep contributing to the top line. Meanwhile, cost-cutting initiatives should drive the bottom line. AstraZeneca also has a promising late-stage pipeline that includes immuno-oncology candidates.  Imfinzi, approved for bladder cancer and currently being evaluated for multiple cancers, is a key drug in the pipeline. AstraZeneca announced many positive developments on the regulatory and pipeline front in 2017. Shares have outperformed the industry in the past one year. Estimate movement has been mixed ahead of Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters.”
  • 1/3/2018 – AstraZeneca was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “AstraZeneca has a strong product portfolio and is one of the key players in the global cardiovascular market. It has been very active on the acquisition and partnership front, and expects to continue pursuing accretive deals. However, AstraZeneca’s core products like Nexium, Seroquel and Crestor are facing generic competition, which is hurting sales. Sales in the diabetes franchise are declining due to intense pricing pressure and competition from market share. Rising competition in the immuno-oncology market is a significant concern. Although AstraZeneca is among the major players in immunotherapy, there are several other companies, big as well as small, looking to develop and bring immunotherapy treatments to market. Sales of another important drug, Symbicort, are declining due to significant pricing pressure on the ICS/LABA class.”
  • 12/29/2017 – AstraZeneca was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating.

Shares of AstraZeneca plc (NYSE:AZN) opened at $34.09 on Tuesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. AstraZeneca plc has a 1-year low of $28.43 and a 1-year high of $36.70. The stock has a market cap of $84,760.00, a PE ratio of 28.89, a P/E/G ratio of 2.03 and a beta of 0.74.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Friday, February 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.86. AstraZeneca had a net margin of 21.83% and a return on equity of 36.38%. The firm had revenue of $5.78 billion during the quarter, compared to analyst estimates of $5.49 billion. During the same quarter in the prior year, the firm posted $1.21 earnings per share. AstraZeneca’s quarterly revenue was up 3.4% on a year-over-year basis. research analysts expect that AstraZeneca plc will post 1.67 EPS for the current fiscal year.

The company also recently disclosed a semiannual dividend, which will be paid on Monday, March 19th. Investors of record on Friday, February 16th will be issued a $0.95 dividend. This represents a dividend yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. AstraZeneca’s dividend payout ratio is currently 116.10%.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply